EHA 2019: Burning out the T-ALL engine: NADK is a new therapeutic target in T-cell Acute Lymphoblastic Leukaemia
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive cancer which is lethal to 15% of…
Browsing: CRISPR-Cas9-based method
T-cell acute lymphoblastic leukaemia (T-ALL) is an aggressive cancer which is lethal to 15% of…